Overview

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Status:
Active, not recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).

Phase:

Phase 3

Details

Lead Sponsor:

Galapagos NV
Gilead Sciences

Collaborators:

Galapagos NV
Gilead Sciences